| Name | Title | Contact Details |
|---|
Elderhaus Inc is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We help healthcare organizations grow intelligently. Our technology enables deeper connections with consumers and physicians through more complete information and the tools to reach them. Payers & Providers can now thrive in the evolving healthcare landscape. Tea Leaves merger with Everyday Health, Inc., created a powerful marketing, communications and growth solution for health systems. Tea Leaves Health’s strategic growth platform, coupled with Everyday Health’s content, audience, data, and expertise in sales and marketing, provides a robust solution for hospital systems to drive their strategic marketing objectives. The combination of Tea Leaves technology and Everyday Health, Inc.’s capabilities creates a powerful tool for hospital systems to reach high-value consumers, positively affect physician relationships and strategically grow health systems through deepening relationships that drive their business.
Zuchelli is a Seaford, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Med-X Global is an LLC formed in the State of New Jersey. We operate as international revenue cycle consultants, third-party medical claims administrators and payment collectors adjudicating emergency medical claims for highly accredited foreign hospitals. Med-X also serves the ancillary emergency provider community in the foreign marketplace to include air and ground ambulance entities as well as premier urgent care centers and physician administered emergency sites. The majority of Med-X`s hospital clients operate clinically sophisticated facilities accredited by the General Heath Council (CSG) while still others are accredited by the Joint Commission International (JCI) reflecting a standard of care that typically meets or even exceeds the U.S. benchmark for quality providers.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.